Vaccines and Global Health: The Week in Review
27 June 2020 :: Number 557
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday evening at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full-text searching of over 9,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click on link below to move to associated content]
A. Milestones :: Perspectives :: Featured Journal Content
B. Emergencies
C. WHO; CDC [U.S., Africa, China]
D. Announcements
E. Journal Watch
F. Media Watch
COVID-19

**Act-Accelerator update**

*Publication of investment cases*  
26 June 2020  
*News release*

:: The tools developed will benefit the whole world, and by saving lives and reducing severe COVID-19 disease, contribute to the goal of protecting health systems and restoring full societal and economic activity globally in the near term, and facilitating high-level control of COVID-19 disease in the medium term.

:: The consolidated investment case calls for US$31.3 billion over the next 12 months[1]. US$3.4 billion has been contributed to date, **resulting in a funding gap of US$27.9 billion**, of which $13.7 billion is urgently needed.

:: **Pillar plans published today show a path to the accelerated development, equitable allocation, and scaled up delivery of 500 million tests to LMIC’s by mid-2021, 245 million courses of treatments to LMICs by mid-2021, and 2 billion vaccine doses, of which 1 billion will be purchased for LMICs, by the end of 2021.**

Today, the Access to COVID-19 Tools Accelerator (ACT-Accelerator) published its consolidated investment case, alongside the costed plans of the member organizations.

Launched at the end of April 2020, at an event co-hosted by the Director-General of the World Health Organization, the President of France, the President of the European Commission, and The Bill & Melinda Gates Foundation, the **ACT-Accelerator brings together governments, health organizations, scientists, businesses, civil society, and philanthropists who have joined forces to speed up an end to the pandemic.**

Since the ACT-Accelerator was launched, the partner organizations have moved fast to develop costed and implementable plans designed to contribute to the end of the pandemic through the accelerated development, equitable allocation, and scaled up delivery of new tools to reduce rapidly mortality and severe disease, protecting health systems and restoring full societal and economic activity globally in the near term, and facilitating high-level control of COVID-19 disease in the medium term.

**ACT-Accelerator investment case and costed plans**

The ACT-Accelerator’s investment case and the plans published by the organizations leading each of the ‘pillars’ show a path to the accelerated development, equitable allocation, and scaled up delivery of 500 million diagnostic tests to LMIC’s by mid-2021, 245 million courses of treatments to LMICs by mid-2021, and 2 billion vaccine doses, of which 50% will go to LMICs by the end of 2021.
To achieve this, the costed plans presented today call for US $31.3 billion in funding for diagnostics, therapeutics and vaccines, of which US$3.4 billion has so far been pledged[2]. An additional US$27.9 billion is therefore needed, including US$13.7 billion to cover immediate needs (i.e. US$17.1 billion is immediately required, of which US$3.4 billion has been pledged).

The investment required is significant, but it pales in significance when compared to the cost of COVID-19: the total cost of the ACT-Accelerator's work is less than a tenth of what the IMF estimates the global economy is losing every month due to the pandemic. 468,000 thousand people have already lost their lives.

The tools developed will benefit the whole world; the ACT-Accelerator pillars will also buy and deliver tools to ensure that LMIC’s have access.

The ACT-Accelerator’s investment case is available here.

COVID-19 Therapeutics Accelerator Donors Launch International Alliance to Connect Research Data Sources and Enable Collaboration

International COVID-19 Data Research Alliance and Workbench will bring together data to accelerate the search for new therapies to fight the pandemic and save lives

SEATTLE, JUNE 26, 2020 - The COVID-19 Therapeutics Accelerator donors and partners today announced the formation of the International COVID-19 Data Research Alliance to accelerate clinical research on COVID-19. Composed of academic institutions, research organizations, life sciences and technology companies, and philanthropies, the International Alliance was created to fight the COVID-19 pandemic, but with the promise for use across other health conditions, including readiness for future pandemics.

Accelerator donors, including the Bill & Melinda Gates Foundation, Chan Zuckerberg Initiative, Mastercard, Minderoo Foundation, and Wellcome, will be founding members of the International Alliance. It will be managed by Health Data Research UK, a national institute for health data science with expertise in harnessing data at scale to improve people's lives, working in partnership with alliance partners from life science companies, academic institutions and clinical research organizations from around the world.

The current pandemic has prompted a great deal of research, but there are few environments where data sets generated by previous studies and trials can be accessed to inform research and development efforts. These data sets could address key questions about the course of COVID-19, how it impacts the body, and what treatments might be effective. In many cases, relevant data sets exist, but researchers cannot easily access or link them for integrated analysis. The International Alliance will provide a variety of ways for researchers to collaborate on data—from pooled to federated analyses—for trustworthy, privacy-protected, and ethical research as determined by a governance board of global specialists in the field.

“In a pandemic, the pathogen has the upper hand. We know very little about it, so access to information becomes an important commodity,” said Trevor Mundel, president of global health
at the Gates Foundation. “By entering into agreements on data sharing up front, we can avoid wasting time going down blind alleys, ultimately saving lives by getting definitive answers to key questions more quickly. This grant to form an international data alliance will accelerate efforts and provide a legacy for future collaboration on pandemics. We encourage others to join us and the other founding partners in this important initiative.”

An Analytical Workbench for Scientific Inquiry
The Workbench will connect to regional and national data infrastructures used by International Alliance members, such as data generated by Therapeutics Accelerator-funded trials, pharmaceutical industry partners, the national BREATHE health data research hub in the United Kingdom, SAIL Databank and others to be confirmed in the coming months. The Workbench, developed by Aridhia Informatics, will enable the discovery of data relevant for answering priority questions from its own repository and federated repositories, and will provide a secure location where analysts can work collectively on a target research hypothesis. Data access and use will be conducted in accordance with the governance requirements of individual data controllers from countries around the world, in a transparent and ethical manner. Authorized users will be able to bring their data to the Workbench and collaborate with others in a secure environment. The Workbench will be designed to encourage and enable responsible data use, including transparency, ethical review, privacy, and data protection...

COVAX: ensuring fair allocation of a COVID-19 vaccine
A global initiative to ensure equitable access to COVID-19 vaccines for all countries
26 June 2020
When a vaccine against COVID-19 becomes available, there will be intense and global demand. Therefore, an ambitious solution is needed to ensure fair allocation of vaccine supply and to make sure no one is left behind. If we are to end this pandemic, we need to stamp out the coronavirus everywhere, not just in the countries that can afford to procure large volumes of a vaccine.

To meet this challenge the COVID-19 Vaccine Global Access Facility (COVAX), part of the ACT Accelerator, has been launched. This initiative, of which CEPI is a proud partner, aims to ensure equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.

COVAX is our best hope of ending the pandemic
COVAX is radical in its ambition but practical in its approach, harnessing the strengths of existing organisations: CEPI will continue to develop, at speed, one of the largest and most advanced COVID-19 vaccine portfolios in the world and will ensure, in collaboration with its industry partners, candidates are ready to be produced at scale. Simultaneously, GAVI will procure and finance (licensed) vaccine and help deploy it to the world, ensuring supply to low-income and middle-income countries and other countries through domestic government budgets.

Ultimately, governments that decide to go it alone risk concentrating their resources in a few potentially unsuccessful vaccine candidates, but by participating in COVAX they will be able to
hedge that risk and increase their chances of success by contributing to a large and diverse portfolio of vaccines. At the same time, through COVAX, governments with limited or no ability to finance their own bilateral procurement can be assured access to life-saving vaccines that would otherwise have been beyond their reach.

Funding COVAX
$18.1 billion will be required to get 2 billion doses of vaccine in 2021. The funding is required immediately, so that we can ensure that accelerated development, manufacturing, procurement, stockpiling, and fair allocation of a vaccine can be achieved. These vital elements must be put in place now, otherwise we could face a delay of up to a year in getting a vaccine to the people who need it most.

Such a delay would be unacceptable, especially against a backdrop of rising coronavirus infections and deaths and an estimated US$375 billion impact on the global economy for every month this pandemic rages on.

Fair allocation of a vaccine
COVAX partners will work together to setup the framework and mechanism required to ensure fair allocation. A methodology is required to fairly allocate a COVID-19 vaccine and it will need to prioritise vaccine supply according to risk groups to reduce the spread of virus and its impact as quickly as possible. Priority populations for the first round of vaccinations will likely include healthcare workers, adults over the age of 65 years, and other high-risk adults with underlying health conditions.

Why we need to act now
Mitigate economic damage – for every month that this pandemic continues, $375 billion is lost from the global economy. Acting now to accelerate development, manufacture, and distribution of a COVID-19 vaccine will save hundreds of thousands of lives and protect the livelihoods of millions more.

Accelerate availability of vaccine – if we follow the traditional course of vaccine development, we could face years of delay. Such a delay will cost lives and trillions of dollars in economic damage. COVAX will enable at-risk investments in production capacity across several candidates now – to ensure that, upon regulatory approval, doses can be made immediately available at scale.

Ensure globally fair allocation and access for low and middle income countries – nobody is safe from COVID-19 until everybody is safe. COVAX not only represents the best solution to end this pandemic, it is also the fairest way to allocate vaccine for all countries to ensure that access can be provided for every country.

With the launch of COVAX, we have a real chance to end this pandemic, but only if governments take a global approach to how they allocate funds for vaccine development, manufacturing, and distribution.

Dr. Richard Hatchett
Chief Executive Officer, CEPI
**Human Vaccines Project**  [to 27 June 2020]
http://www.humanvaccinesproject.org/media/press-releases/

**COVID Report**
"What Worries Me Is That People Do Trust Vaccines"

Interview with Paul A. Offit, M.D.

*We asked for his thoughts on the clinical trials of COVID-19 vaccine candidates prioritized by Operation Warp Speed. A slightly edited version of our conversation appears below.*

**Are the vaccines that are being prioritized by Operation Warp Speed in the US the most likely to work or just the fastest to produce?**

I think they’re just the fastest to be produced because for the most part they are all genetic vaccines; mRNA or replication-defective simian or human adenoviruses where you can just sort of plug and play. You know the gene you’re interested in—it’s the gene that codes for the SARS-CoV-2 surface protein, the Spike protein—so you just plug it in. It’s much easier to make than an inactivated viral vaccine, a live attenuated viral vaccine, or a purified protein vaccine.

There is nothing that says these vaccines will be more likely to be safe or effective than existing vaccine strategies. I don’t know how the decision was made to prioritize these candidates. I’m on the NIH ACTIV group but we weren’t involved in picking those vaccines.

**Is there a potential trade-off between speed and safety/efficacy in the race to develop vaccines for SARS-CoV-2?**

I’ll tell you eight months from now. The Phase III trials will tell all, assuming that we do the Phase III trials that we’ve been asking to do, which will involve at least 20,000 vaccine recipients and 10,000 placebo recipients. If we at least do that, we’ll see.

We have no experience with those strategies. There are no mRNA vaccines or replication-defective simian or human adenovirus vaccines on the market. They don’t exist. With messenger RNA, the mRNA itself is a very labile molecule that is rapidly degraded, so that doesn’t worry me. But do you know how many particles are given when you give a replication defective virus vaccine? Roughly 100 billion particles. Might that invoke some aberrant immune response? It’s possible. That’s why you have to enroll at least 20,000 volunteers in the vaccine arm to rule out an uncommon side effect. You’re not going to be able to rule out rare side effects until you put the vaccine in 20 million people.

**Are there plans now to test any of these COVID-19 vaccine candidates in children?**

Not initially. When the vaccine rolls out, then children will be part of those studies. For children, you have to hold this vaccine to an especially high standard of safety because although there is this post-infection Kawasaki-like disease, it’s still the rare child that dies of this virus. When you consider that there 114,000 people who have died in the US from COVID-19, how many have been children? It has to be fewer than 20, whereas 160 children died from flu this year.

**Does releasing a vaccine so quickly risk increasing the distrust of vaccines, particularly among certain groups?**
The true anti-vaccine activists, which is to say the conspiracy theorists, will still find some reason to hate this vaccine no matter how safe or effective it is, even though those reasons won’t be valid. I think the focus by the media has been wrong to some extent. When people say there’s a distrust of vaccines, I don’t think that’s true. What worries me is that people do trust vaccines. Very much so. Parents in this country are asked to give children 14 different vaccines in the first years of life—that can be as many as 27 inoculations during that time period and as many as five shots at one time—to prevent diseases most parents have never seen, using biological fluids most parents don’t understand. They do trust us. I think we risk that trust if we rush this along and don’t do the type of Phase III testing that we need to do for this vaccine. We also need to manage expectations when we do release a vaccine to say that we don’t know if it causes rare side effects, but we’re looking, and we don’t know how long the duration of immunity will be because we’ll learn as we go. You will never, ever convince the anti-vaccine people because data doesn’t convince them.

**When vaccines are available, what percentage of the population will likely need to be vaccinated to establish herd immunity?**

It’s a guess. It is a combination of two factors: the contagiousness of the virus and the effectiveness of the vaccine. With measles, for example, you have a very, very contagious virus—the most contagious of the vaccine-preventable diseases—but you have an extraordinarily effective vaccine, so you need to have just over 90 percent of the population vaccinated. With polio, we started to see a decrease in the spread of polio when we started to get to 40-50 percent immunization rates. With rotavirus, by the time you got to 60-70 percent immunization rates, the disease dramatically declined. I think if you get to 70-80 percent with a COVID-19 vaccine you’ll see a dramatic reduction in the incidence of this disease, as a guess.

**What keeps you up at night given all of this?**

There is a system, which I trust, that has been in place since the 1950s to make sure that the vaccines that are brought into this country are tested as much as is reasonable to mitigate risks regarding safety and efficacy. This system involves the NIH, the CDC [US Centers for Disease Control and Prevention], and the FDA [US Food and Drug Administration]. As long as that system stays in place, I’m good. What worries me is that this system could be perturbed by an administration that perturbs the science. This is an administration that took the words climate change off the EPA’s [US Environmental Protection Agency’s] website. This is an administration that pushed hydroxychloroquine [as a COVID-19 treatment] and got the FDA to approve it—a product that had never been shown to work, was known to have a certain level of toxicity, and that ended up doing more harm than good. That was the FDA at its worst. They let themselves be pushed around and if that happens here, that would be a problem.

::: EMERGENCIES :::

**Coronavirus [COVID-19]**

*Public Health Emergency of International Concern (PHEIC)*
WHO - Situation report - 158
Coronavirus disease 2019 (COVID-19)
26 June 2020
Confirmed cases :: 9 653 048
Confirmed deaths :: 491 128
Countries, areas or territories with cases :: 216

Highlights
:: On 25 June, Health Minister Jens Spahn of Germany, and Solidarity and Health Minister Olivier Veran of France, visited WHO headquarters. During a press briefing they expressed their solidarity and additional support to both COVID-19 response and WHO’s core programmes.

Yesterday the Ebola virus disease outbreak in the northeast of the Democratic Republic of the Congo was declared over after nearly two years. The WHO Regional Office for Africa and partners are now building on the Ebola response to tackle COVID-19 in the country. Additionally, WHO is supporting other countries in Africa as the COVID-19 pandemic accelerates in the region.

:: In a press briefing yesterday, Dr Hans Henri P. Kluge, WHO Regional Director for Europe, spoke about COVID-19 in the region and how digital technology and artificial intelligence can empower people and play a leading role in optimizing efforts to control transmission of the disease.

Emergencies

Ebola – DRC+
Public Health Emergency of International Concern (PHEIC)

Final Statement on the 8th meeting of the International Health Regulations (2005)
26 June 2020 Statement
Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo (provinces of Ituri, North Kivu, and South Kivu) on 26 June 2020

...Conclusions and Advice

The Committee agreed that the current situation in the Ituri, North Kivu, and South Kivu provinces no longer constitutes a public health emergency of international concern.

The Committee emphasized the importance of continued donors’ funding and human resources to operationalize the 90-day day national response plan.

The Committee provided the following advice to the Director-General for his issuance as revised Temporary Recommendations, in accordance with Article 15(1) of the IHR (2005) “...Temporary Recommendations may be modified or extended as appropriate, including after it has been determined that a public health emergency of international concern has ended, at which time other temporary recommendations may be issued as necessary for the purpose of preventing or promptly detecting its recurrence [...] These Temporary Recommendations shall automatically expire three months after their issuance.”...
Based on this advice, the report made by the affected State Party and the currently available information, the Director-General accepted the Committee's assessment and on 26 June 2020 declared the end of the Public Health Emergency of International Concern (PHEIC) for this event...

25 June 2020 News release
10th Ebola outbreak in the Democratic Republic of the Congo declared over; vigilance against flare-ups and support for survivors must continue

Today marks the end of the 10th outbreak of Ebola virus disease in the Democratic Republic of the Congo (DRC). This long, complex and difficult outbreak has been overcome due to the leadership and commitment of the Government of the DRC, supported by the World Health Organization (WHO), a multitude of partners, donors, and above all, the efforts of the communities affected by the virus.

WHO congratulates all those involved in the arduous and often dangerous work required to end the outbreak, but stresses the need for vigilance. Continuing to support survivors and maintaining strong surveillance and response systems in order to contain potential flare-ups is critical in the months to come.

"The outbreak took so much from all of us, especially from the people of DRC, but we came out of it with valuable lessons, and valuable tools. The world is now better-equipped to respond to Ebola. A vaccine has been licensed, and effective treatments identified," said WHO Director-General Dr Tedros Adhanom Ghebreyesus.

“We should celebrate this moment, but we must resist complacency. Viruses do not take breaks. Ultimately, the best defence against any outbreak is investing in a stronger health system as the foundation for universal health coverage.”

The outbreak, declared in North Kivu on 1 August 2018, was the second largest in the world, and was particularly challenging as it took place an active conflict zone. There were 3470 cases, 2287 deaths and 1171 survivors.

Led by the DRC Government and the Ministry of Health and supported by WHO and partners, the more than 22-month-long response involved training thousands of health workers, registering 250 000 contacts, testing 220 000 samples, providing patients with equitable access to advanced therapeutics, vaccinating over 303 000 people with the highly effective rVSV-ZEBOV-GP vaccine, and offering care for all survivors after their recovery.

The response was bolstered by the engagement and leadership of the affected communities. Thanks to their efforts, this outbreak did not spread globally. More than 16 000 local frontline responders worked alongside the more than 1500 people deployed by WHO. Support from donors was essential, as was the work of UN partner agencies, national and international NGOs, research networks, and partners deployed through the Global Outbreak Alert and Response Network. Hard work to build up preparedness capacities in neighbouring countries also limited the risk of the outbreak expanding...
Ebola Outbreak in DRC 98: 23 June 2020

Situation Update

In Ituri, North Kivu and South Kivu provinces of the Democratic Republic of the Congo, no new confirmed cases of EVD have been reported since 27 April 2020...

Conclusion

Tuesday 23 June 2020 marks 41 days with no new cases of EVD since the Ministry of Health began its 42-day countdown to the declaration of the end of the EVD outbreak in Ituri, North Kivu and South Kivu. Maintaining a robust surveillance system in order to detect, isolate, test and treat new suspected cases as early as possible will remain crucial for this response even after the declaration of the end of the outbreak, as will be coordination, among partners, authorities and communities and EVD survivor advocacy.

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

Polio this week as of 24 June 2020

:: Dr Fiona Braka, Immunization Team Lead for WHO Nigeria, speaks about fighting polio outbreaks and toppling gender barriers.

Summary of new viruses this week (AFP cases and ES positives):

:: Afghanistan: three WPV1 cases, two WPV1 positive environmental samples and four cVDPV2 cases
:: Pakistan: two WPV1 cases, and five WPV1 positive environmental samples
:: Cameroon: one cVDPV2 positive environmental sample
:: Chad: 23 cVDPV2 cases
:: Côte d’Ivoire: eight cVDPV2 positive environmental samples
:: Togo: two cVDPV2 cases

WHO Grade 3 Emergencies [to 27 June 2020]

Democratic Republic of the Congo
:: Ebola Outbreak in DRC 98: 23 June 2020
[See Ebola above for detail]

Nigeria - No new digest announcements identified
Somalia - No new digest announcements identified
South Sudan - No new digest announcements identified
Syrian Arab Republic - No new digest announcements identified
Yemen - No new digest announcements identified

:::

**WHO Grade 2 Emergencies** [to 27 June 2020]

**Burkina Faso** [in French]
:: L'OMS appuie la construction des unités de triage des patients dans la lutte contre le COVID-19 21 juin 2020

Angola - No new digest announcements identified
Afghanistan - No new digest announcements identified
Burundi - No new digest announcements identified
Cameroon - No new digest announcements identified
Central African Republic - No new digest announcements identified
Ethiopia - No new digest announcements identified
Iraq - No new digest announcements identified
Libya - No new digest announcements identified
Malawi - No new digest announcements identified
Measles in Europe - No new digest announcements identified
MERS-CoV - No new digest announcements identified
Myanmar - No new digest announcements identified
Niger - No new digest announcements identified
occupied Palestinian territory - No new digest announcements identified
Sudan - No new digest announcements identified
Ukraine - No new digest announcements identified
Zimbabwe - No new digest announcements identified

:::

**WHO Grade 1 Emergencies** [to 27 June 2020]

Chad - No new digest announcements identified
Djibouti - Page not responding at inquiry
Kenya - No new digest announcements identified
Mali - No new digest announcements identified
Namibia - viral hepatitis - No new digest announcements identified
Tanzania - No new digest announcements identified

:::

**UN OCHA – L3 Emergencies**

*The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises.*

**Syrian Arab Republic**
:: Recent Developments in Northwest Syria - Situation Report No. 16 - As of 26 June 2020
Yemen - No new digest announcements identified

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

CYCLONE IDAI and Kenneth
:: 26 June 2020  Zimbabwe Situation Report, 26 June 2020

EBOLA OUTBREAK IN THE DRC - No new digest announcements identified

WHO & Regional Offices [to 27 June 2020]
26 June 2020  News release
Act-Accelerator update

26 June 2020  Statement
Final Statement on the 8th meeting of the International Health Regulations (2005)

25 June 2020  News release
10th Ebola outbreak in the Democratic Republic of the Congo declared over; vigilance against flare-ups and support for survivors must continue

26 June 2020  News release
IOC joins forces with WHO and the United Nations to fight COVID-19
On Olympic Day, 23 June 2020, the International Olympic Committee and WHO together with the United Nations launch a partnership to encourage individuals and communities around the world to be #HEALTHYTogether. The three partners and Olympic athletes will spotlight the global collaboration needed to stay healthy and reduce the spread and impact of COVID-19...

Weekly Epidemiological Record, 26 June 2020, vol. 95, 26 (pp. 281–300)
:: Index of countries/areas
:: Index, Volume 95, 2020, Nos. 1–26
:: Progress towards polio eradication – worldwide, January 2018–March 2020
:: Progress towards rubella elimination – Western Pacific Region, 2000–2019

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Building on Ebola response to tackle COVID-19 in DRC  25 June 2020
WHO Region of the Americas PAHO
No new digest content identified.

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: WHO/Europe and EU deliver critical supplies to the COVID-19 frontline 26-06-2020
:: Digital health is about empowering people 25-06-2020

WHO Eastern Mediterranean Region EMRO
:: EU, WHO to strengthen Sudan’s COVID-19 response and health system
   Khartoum, 24 June 2020 — The World Health Organization welcomes a generous
collection of 11.5 million Euros from the European Union to fight COVID-19 in Sudan and
improve the country’s overall health system.

WHO Western Pacific Region
No new digest content identified.

CDC/ACIP [to 27 June 2020]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases
Transcript for the CDC Telebriefing Update on COVID-19
Friday, June 26, 2020

CDC Marks the End of the 2018 Ebola Outbreak in Eastern Democratic Republic of the Congo
Thursday, June 25, 2020

CDC updates, expands list of people at risk of severe COVID-19 illness
Thursday, June 25, 2020

...COVID-19 risk related to underlying medical conditions
CDC also updated the list of underlying medical conditions that increase risk of severe illness
after reviewing published reports, pre-print studies, and various other data sources. CDC
experts then determined if there was clear, mixed, or limited evidence that the condition
increased a person’s risk for severe illness, regardless of age.

There was consistent evidence (from multiple small studies or a strong association from a large
study) that specific conditions increase a person’s risk of severe COVID-19 illness:
:: Chronic kidney disease
:: COPD (chronic obstructive pulmonary disease)
:: Obesity (BMI of 30 or higher)
:: Immunocompromised state (weakened immune system) from solid organ transplant
Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies
::: Sickle cell disease
::: Type 2 diabetes

These changes increase the number of people who fall into higher risk groups. An estimated 60 percent of American adults have at least one chronic medical condition. Obesity is one of the most common underlying conditions that increases one’s risk for severe illness – with about 40 percent of U.S. adults having obesity. The more underlying medical conditions people have, the higher their risk...

Africa CDC [to 27 June 2020]
http://www.africacdc.org/
News
Ecobank and Africa CDC hold digital public forum on COVID-19
Accra, Ghana – June 24, 2020. Ecobank, in partnership with the Africa Centres for Disease Control and Prevention (CDC), held a public forum yesterday to engage customers and the public on the effects of COVID-19 on health in Africa as well as on individuals and businesses. Held virtually via Facebook Live and YouTube, the forum attracted hundreds of participants, in real time, with many shares and downloads of the event...

China CDC
http://www.chinacdc.cn/en/
No new digest content identified.

National Health Commission of the People's Republic of China
http://en.nhc.gov.cn/
News
June 27: Daily briefing on novel coronavirus cases in China
On June 26, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 21 new cases of confirmed infections, 1 new case of suspected infections, and no deaths.

Officials: Testing key to virus control
More than 90 million nucleic acid tests for novel coronavirus have been conducted across China, with testing capacity for the deadly virus increasing significantly, the top health authority said on June 24.

China’s daily nucleic acid testing capacity tops 3m: official
2020-06-26
**Paul G. Allen Frontiers Group**  [to 27 June 2020]
*News*
*No new digest content identified.*

**BARDA – U.S. Department of HHS**  [to 27 June 2020]
https://www.phe.gov/about/barda/Pages/default.aspx
June 23, 2020:
**BARDA partners with MBio Diagnostics to develop an in vitro point-of-care serology test for the detection of human anti-SARS-CoV-2 antibodies from whole blood samples**

**BMGF - Gates Foundation**  [to 27 June 2020]
http://www.gatesfoundation.org/Media-Center/Press-Releases
JUNE 26, 2020
**COVID-19 Therapeutics Accelerator Donors Launch International Alliance to Connect Research Data Sources and Enable Collaboration**
International COVID-19 Data Research Alliance and Workbench will bring together data to accelerate the search for new therapies to fight the pandemic and save lives
*[See Perspectives above for detail]*

**Bill & Melinda Gates Medical Research Institute**  [to 27 June 2020]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
*No new digest content identified.*

**CARB-X**  [to 27 June 2020]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
06.22.2020 |
**CARB-X funds University of Queensland to accelerate the development of a new class of last-resort antibiotics to treat deadly superbug infections**
CARB-X is awarding up to US$3.83 million to The University of Queensland’s Institute for Molecular Bioscience, Brisbane, Australia, to develop a new class of antibiotics to treat serious drug-resistant bacterial infections

**CEPI – Coalition for Epidemic Preparedness Innovations**  [to 27 June 2020]
COVAX: ensuring fair allocation of a COVID-19 vaccine

A global initiative to ensure equitable access to COVID-19 vaccines for all countries

[See Perspectives above for detail]

25 Jun 2020
Stevanato Group signs an agreement with CEPI to provide pharma glass vials for 2 billion doses of COVID-19 vaccines under development

This supply is part of CEPI’s efforts to rapidly speed up the vaccine development timeline through making progress on manufacturing in parallel with the clinical development of COVID-19 candidate vaccines.

23 Jun 2020
CEPI-funded COVID-19 vaccine candidates progress to clinical trials

Clover Biopharmaceuticals have started Phase 1 trials of its COVID-19 candidate vaccine. CureVac and the University of Queensland are also set to begin clinical trials shortly.

Clinton Health Access Initiative, Inc. (CHAI) [to 27 June 2020]
https://clintonhealthaccess.org/
News & Press Releases
No new digest content identified.

EDCTP [to 27 June 2020]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.

Emory Vaccine Center [to 27 June 2020]
http://www.vaccines.emory.edu/
No new digest content identified.

European Medicines Agency [to 27 June 2020]
News & Press Releases
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020
CHMP, Last updated: 26/06/2020
Press release: First COVID-19 treatment recommended for EU authorisation
Last updated: 25/06/2020

Press release: Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines
Last updated: 24/06/2020

European Vaccine Initiative  [to 27 June 2020]
http://www.euvaccine.eu/
Latest News
No new digest content identified.

FDA  [to 27 June 2020]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements


June 24, 2020 - Coronavirus (COVID-19) Update: Daily Roundup June 24, 2020

June 24, 2020 - Coronavirus (COVID-19) Update: Joint Statement from USDA and FDA on Food Export Restrictions Pertaining to COVID-19


Fondation Merieux  [to 27 June 2020]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi  [to 27 June 2020]
https://www.gavi.org/
News releases
26 June 2020

Gavi Board calls for global access to COVID-19 vaccines
:: Gavi Board shows support for continued work on COVAX Facility: a global, coordinated mechanism designed to ensure rapid and equitable access to safe and efficacious COVID-19 vaccines to as broad a global population as possible
:: The Board also discussed the role Gavi will play in an expansion in cold chain capacity in developing countries to deploy COVID-19 vaccines, as well as potentially diagnostics and treatments
New flexibilities and measures put in place to help countries deal with unprecedented impact of COVID-19 on immunisation programmes, as well as revised gender policy to guide Gavi’s programmes

25 June 2020
First-of-its-kind vaccine agreement helps end Ebola outbreak in eastern DRC
DRC government and WHO declare over the long-running Ebola outbreak in North Kivu, South Kivu and Ituri provinces after more than 50 days without a case
A first-of-its-kind agreement between Gavi, the Vaccine Alliance and the vaccine manufacturer helped create a stockpile of Ebola vaccines that protected more than 303,000 people as part of the outbreak response
Dr Seth Berkley: “This is an important day for the DRC, which shows the key role the new Ebola vaccine can play in ending Ebola outbreaks now and in the future”

24 June 2020
Gavi a top performer in leading transparency index

23 June 2020
DRC recognised for its immunisation efforts

GHIT Fund [to 27 June 2020]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

Global Fund [to 27 June 2020]
News
Global Fund Appoints New Chief Financial Officer
26 June 2020
The Global Fund to Fight AIDS, Tuberculosis and Malaria today announced the appointment of Adda Faye as Chief Financial Officer, as the Global Fund works to optimize its financial resource management at this critical moment in global public health financing...
Faye brings over 15 years of experience in strategic financial management and a deep understanding of the Global Fund’s financial and administrative functions. Before her selection through a competitive search process, Faye served as the Global Fund’s interim Chief Financial Officer since February 2020...

News
Global Fund COVID-19 Report: Deaths from HIV, TB and Malaria Could Almost Double in 12 Months Unless Urgent Action is Taken
24 June 2020
A new report [ download in English ] released by the Global Fund today estimates that countries affected by HIV, tuberculosis and malaria urgently need US$28.5 billion to protect the extraordinary progress achieved in the fight against the three diseases in the past two decades.
The report, *Mitigating the Impact of COVID-19 on Countries Affected by HIV, Tuberculosis and Malaria*, was released today to highlight the impact of COVID-19 and resources needed to protect progress against HIV, TB and malaria – diseases that still kill more than 2.4 million people a year. Since 2002, the Global Fund partnership has helped save more than 32 million lives and cut HIV, TB and malaria deaths by nearly half since the peak of the epidemics. The COVID-19 pandemic now threatens to reverse that progress.

Aside from the direct toll of COVID-19, which could be catastrophic in the most vulnerable countries, estimates suggest deaths from HIV, TB and malaria could as much as double if systems for health are overwhelmed, treatment and prevention programs are disrupted, and resources are diverted...

*News*

**Global Fund Ranks in Top Category for Transparency**
24 June 2020

**Hilleman Laboratories**  [to 27 June 2020]
*No new digest content identified.*

**Human Vaccines Project**  [to 27 June 2020]

*COVID Report*  
"*What Worries Me Is That People Do Trust Vaccines*"
Interview with Paul A. Offit, M.D.
[See Perspectives above for full text]*

**IAVI**  [to 27 June 2020]
[https://www.iavi.org/newsroom](https://www.iavi.org/newsroom)
*Press Releases*
*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
*Selected Statements, Press Releases, Research*  
*No new digest content identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**
[https://www.igbamedicines.org/](https://www.igbamedicines.org/)
*News*  
*No new digest content identified.*

**IFFIm**
Innovative Humanitarian Financing Forum charts way forward

25 Jun 2020

Leaders in business and philanthropy explore pathways to catalyse change through public-private financing

As COVID-19 continues to spread, the world is witnessing the speed and scale with which a local health challenge can grow into a global crisis. How can public and private sectors work together to increase the scale and scope of funding required to proactively address social causes—and potentially avert crises from future global threats?

This question is at the center of discussions within the Innovative Humanitarian Financing Forum (IHFF), a roundtable of practitioners and stakeholders in innovative finance initiated by Cyrus Ardalan, IFFIm Board Chair, and Simon Meldrum, Innovative Finance Specialist at the British Red Cross.

The Forum is bringing together representatives of public and private institutions in business, banking, charities and humanitarian organisations to explore how novel financial tools and instruments could expand resources for urgent humanitarian needs, from health emergencies and education to sanitation, hygiene and climate change.

The IHFF convened virtually on May 18 with more than 30 participants from 17 organisations...

---

**IFRC** [to 27 June 2020]


Selected Press Releases, Announcements

**Europe**

**Red Cross and Red Crescent urges continued vigilance amid alarming resurgence of COVID-19 in Europe**

Budapest, 26 June 2020 – As a resurgence in COVID-19 cases is reported in many parts of Europe and total deaths on the continent near 200,000, the International Federation of Red Cross and Red Crescent Societies (IFRC) calls on communities to continue ...

26 June 2020

---

**IVAC** [to 27 June 2020]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates

**Commentary: The pneumococcal vaccine is bolstering child health in Nepal**

By Rose Weeks

New evidence shows fewer children hospitalized with bacterial pneumonia, but countries must be vigilant to avoid a drop in vaccine coverage during COVID-19

---

**IVI** [to 27 June 2020]

http://www.ivi.int/

Selected IVI News & Announcements

No new digest content identified.
**JEE Alliance** [to 27 June 2020]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

**MSF/Médecins Sans Frontières** [to 27 June 2020]
http://www.msf.org/
Latest [Selected Announcements]
DRC Ebola outbreaks
**Six lessons learned as Ebola outbreak in northeastern DRC ends**
Project Update 26 Jun 2020

DRC Ebola outbreaks
**Crisis update - June 2020**
Crisis Update 26 Jun 2020

DRC Ebola outbreaks
**DRC's tenth Ebola outbreak**
Crisis Update 25 Jun 2020

South Sudan
**Intense fighting in eastern South Sudan once again forces thousands to flee**
Statement 24 Jun 2020

United States of America
**MSF helping to curb COVID-19 in nursing homes in US**
Project Update 23 Jun 2020

**National Vaccine Program Office** - U.S. HHS [to 27 June 2020]
https://www.hhs.gov/vaccines/about/index.html
NVAC 2020 Meetings
**September 23-24, 2020 Meeting (Virtual)**

**NIH** [to 27 June 2020]
Selected News Releases
**NIH investigators hope CD47 study leads to broad-spectrum infectious diseases immunotherapy**
   June 23, 2020 — Finding provides a potential target for an immunotherapy that might be applied to a wide range of infectious diseases.

**Experts identify steps to expand and improve antibody tests in COVID-19 response**
   June 23, 2020 — NIH workshop attendees review capabilities, limits of SARS-CoV-2 serology testing.
PATH [to 27 June 2020]
https://www.path.org/media-center/
Selected Announcements
No new digest content identified.

Sabin Vaccine Institute [to 27 June 2020]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 27 June 2020]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
26 June 2020
Harm reduction continues for people who use drugs during COVID-19 in Côte d’Ivoire

24 June 2020
Survey shows that many people lack multimonth HIV treatment in Latin America

UNICEF [to 27 June 2020]
https://www.unicef.org/media/press-releases
Selected Press releases/Announcements
News note
26/06/2020
UNICEF comment on malnutrition in Afghanistan at the Geneva Palais briefing
This is a summary of what was said by Marixie Mercado, UNICEF spokesperson – to whom quoted text may be attributed – at today's press briefing at the Palais des Nations in Geneva

Press release
26/06/2020
“To control COVID-19, we have to make hand hygiene accessible to all” – UNICEF and WHO
Joint statement by Henrietta Fore, Executive Director of UNICEF, and Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, on the launch of the ‘Hand Hygiene for All’ joint initiative

Press release
26/06/2020
Despite disruptions, UNICEF delivers critical life-saving supplies to over 100 countries in response to the COVID-19 pandemic
In 2019, UNICEF procured a record US$3.826 billion in goods and services for children in 150 countries and saved US$363.3 million for governments and donors by leveraging its purchasing power and strategic procurement approaches, in collaboration with par

Press release 26/06/2020
**Yemeni children face deadly hunger and aid shortages as COVID-19 pandemic spreads - UNICEF**

Number of malnourished children could reach 2.4 million by end of year, a 20 per cent increase

Press release 25/06/2020
**UNICEF welcomes end of 23 month-long Ebola outbreak in eastern DRC and calls for additional support as country tackles new outbreak in north-west**

Statement 23/06/2020
**UNICEF Executive Director Henrietta Fore’s remarks at the UN Security Council Open Debate on Children and Armed Conflict**

This is a summary of what was said by Henrietta Fore, UNICEF Executive Director – to whom quoted text may be attributed – at today’s Security Council Open Debate at the United Nations in New York. Checked against delivery.

Press release 23/06/2020
**Urgent action needed to safeguard futures of 600 million South Asian children threatened by COVID-19: UNICEF**

Cash transfers and other measures can prevent families slipping into poverty

GENEVA/KATHMANDU/NEW YORK, 23 JUNE 2020 – The COVID-19 pandemic is unravelling decades of health, education and other advances for children across South Asia, and governments must take urgent action to prevent millions of families from slipping back into poverty, UNICEF said in a new report released today.

With the pandemic expanding rapidly across a region that contains a quarter of the world’s population, Lives Upended describes the disastrous immediate and longer-term consequences that the virus and the measures to curb it have had on 600 million children and the services they depend on....

According to the report, immunization, nutrition and other vital health services have been severely disrupted, potentially threatening the lives of up to 459,000 children and mothers over the next six months. Food insecurity is growing: A UNICEF survey in Sri Lanka showed that 30 per cent of families have reduced their food consumption. In Bangladesh, some of the poorest families are unable to afford three meals a day...

**Unitaid** [to 27 June 2020]
[https://unitaid.org/](https://unitaid.org/)
**Featured News**
22 June 2020
£2.2m for Liverpool-led initiative to rapidly identify COVID-19 ‘game changing’ drugs

... The AGILE COVID-19 Drug Testing Initiative, led by the University of Liverpool and involving researchers from the Liverpool Tropical School of Medicine, Southampton Clinical Trials Unit and NIHR Liverpool and Broadgreen Clinical Research Facility, has been established to enable the rapid clinical evaluation of potential COVID-19 therapeutics.

Saye Khoo, Professor of Molecular and Clinical Pharmacology, University of Liverpool, said: “AGILE uses the most modern and innovative statistical methods which allows for multiple drugs to be tested in parallel, and to remove or add treatments faster than ever before, based on results of safety and efficacy.”.

Vaccination Acceptance Research Network (VARN) [to 27 June 2020]
https://vaccineacceptance.org/news.html#header1-2r
Announcements
No new digest content identified.

Vaccine Confidence Project [to 27 June 2020]
http://www.vaccineconfidence.org/
Latest News & Archive
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 27 June 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

Wellcome Trust [to 27 June 2020]
https://wellcome.ac.uk/news
Opinion | 26 June 2020
Four lessons from past epidemics to guide us in the search for COVID-19 treatments by Josie Golding

Opinion | 22 June 2020
Our trans inclusion policy is the latest step in making Wellcome more inclusive by Kathy Poole

Opinion | 22 June 2020
Treatments will take the fear and helplessness out of coronavirus – here’s how businesses can help find them
Jeremy Farrar, Director Wellcome
Science will show us the way out of the COVID-19 pandemic. And businesses and philanthropy can play a major role by stepping up to fund coronavirus treatments, as well as vaccines and tests.
The Wistar Institute [to 27 June 2020]
Press Release
Jun. 25, 2020
The Wistar Institute & Allevi Inc. Collaborate on 3D Bioprinting Project to Advance COVID-19 Research
Allevi 3D printed lung models will be used to study SARS-CoV-2 mechanisms of disease progression

WFPHA: World Federation of Public Health Associations [to 27 June 2020]
https://www.wfpha.org/
Latest News
No new digest content identified.

World Organisation for Animal Health (OIE) [to 27 June 2020]
Press Releases
Preserving our future by protecting wildlife health
Today more than ever, the international health community recognises the importance of maintaining a global perspective and foresight on wildlife health and biodiversity and their inextricable connection with veterinary and human public health.
Paris, 22 June 2020 – Anthropogenic impact on the environment alters the delicate balance of ecosystems and their health. The recent spillover events, such as SARS and Ebola, have been associated with poorly regulated or managed wildlife trade and the lack of awareness of risks associated to human contact with potential reservoirs or intermediate hosts. Therefore, the suggestion that COVID-19 originated in wildlife highlights the importance of addressing health risks at the human-animal-ecosystem interface, as well as the need for integrated surveillance systems, all while preserving animal welfare and biodiversity.
Whether in the wild or in captivity, the health of wildlife represents a key component of global health. The OIE Working Group on Wildlife, formed in 1994, informs and advises the OIE on this matter. An overview of the main activities carried out by the group over last year is presented...
Improving wildlife disease surveillance
Wildlife disease surveillance allows early detection of potentially impactful animal and human health threats and implementation of appropriate control measures. This can only be achieved by timely reporting the occurrence of wild and domestic animal diseases. The OIE Working Group on Wildlife regularly encourages countries to notify wildlife diseases through the World Animal Health Information System (WAHIS) - Wild platform...

::::::

ARM [Alliance for Regenerative Medicine] [to 27 June 2020]
Press Releases
No new digest content identified.
BIO  [to 27 June 2020]
Press Releases
As Companies Work Around the Clock to Address COVID-19, BIO Outlines Key Policy Priorities to Prevent the Next Pandemic
June 23, 2020
BIO Board Member Dr. Gerberding to testify this morning The Senate Committee on Health, Education, Labor and Pensions, chaired by Senator Lamar Alexander, will hold an important hearing today to examine lessons learned from the current global...

DCVMN – Developing Country Vaccine Manufacturers Network  [to 27 June 2020]
http://www.dcvmn.org/
News
No new digest content identified.

IFPMA  [to 27 June 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

ICBA – International Council of Biotechnology Associations  [to 27 June 2020]
https://internationalbiotech.org/
News
No new digest content identified.

PhRMA  [to 27 June 2020]
http://www.phrma.org/
Selected Press Releases, Statements
No new digest content identified.

* * * * *

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

**American Journal of Infection Control**
July 2020 Volume 48, Issue 7, p733-858
http://www.ajicjournal.org/current

*Commentary*

**Weathering COVID-19 storm: Successful control measures of five Asian countries**
Ning Lu, Kai-Wen Cheng, Nafees Qamar, Kuo-Cherh Huang, James A. Johnson
p851–852
Published online: April 29, 2020
:: COVID-19 control measures taken by 5 Asian countries first hit by coronavirus.
:: Singapore took proactive measures of border controls and extensive contact tracing.
:: Taiwan seized border control and strict home quarantine with the use of big data.
:: South Korea executed widespread testing and contact tracing.
:: Japan promoted measures of social distancing.

**American Journal of Preventive Medicine**
July 2020 Volume 59, Issue 1, p1-148
http://www.ajpmonline.org/current

*Research Articles*

**Shingles Vaccination of U.S. Adults Aged 50–59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine**
Peng-jun Lu, Mei-chuan Hung, Anup Srivastav, Walter W. Williams, Kathleen L. Dooling
p21–31
Published online: May 7, 2020

**American Journal of Public Health**
July 2020 110(7)
http://ajph.aphapublications.org/toc/ajph/current

*AJPH EDITOR'S CHOICE*

**We're Not All in This Together: On COVID-19, Intersectionality, and Structural Inequality**
Other Race/Ethnicity, Human Rights, Infections, Socioeconomic Factors, Epidemiology, Ethics, Race/Ethnicity
Lisa Bowleg

*AJPH EDITORIALS*

**COVID-19**

**The Public Health We Need**
Infections, Public Health Practice, Epidemiology, Health Policy
Alfredo Morabia
110(7), pp. 923–924

*INTRODUCTION TO THE SECTION*
A Public Health Perspective in the Times of COVID-19
Global Health, Infections, Epidemiology, Other Infections
Daniel Tarantola, Wendy E. Parmet, Michael C. Costanza and Stella Yu

INFORMATION
COVID-19: The First Posttruth Pandemic
Immunization/Vaccines, Infections, Health Law, Public Health Practice, Other Infections, Health Promotion
Wendy E. Parmet and Jeremy Paul
110(7), pp. 945–946

Publication Ethics During Public Health Emergencies Such as the COVID-19 Pandemic
Global Health, Infections, Health Policy, Writing/Reviewing/Publishing, Ethics, Other Infections
Maxwell J. Smith, Ross E.G. Upshur and Ezekiel J. Emanuel
110(7), pp. 947–948

Accurate Statistics on COVID-19 Are Essential for Policy Guidance and Decisions
Infections, Epidemiology, Statistics/Evaluation/Research, Other Infections, Surveillance, Other Statistics/Evaluation/Research
Neil Pearce, Jan P. Vandenbroucke, Tyler J. VanderWeele and Sander Greenland
110(7), pp. 949–951

Producing Independent, Systematic Review Evidence: Cochrane’s Response to COVID-19
Public Health Practice, Epidemiology, Health Policy, Writing/Reviewing/Publishing, Statistics/Evaluation/Research, Other Statistics/Evaluation/Research
Lisa A. Bero
110(7), pp. 952–953

VACCINES
The School Vaccination Assessment Program: A Physician’s Perspective
Immunization/Vaccines, Prevention, Child and Adolescent Health, School Health, Other Child and Adolescent Health
Joshua T. B. Williams
110(7), pp. 927–928

VACCINE EXEMPTIONS
The Emergence of Spatial Clustering in Medical Vaccine Exemptions Following California Senate Bill 277, 2015–2018
Immunization/Vaccines, Health Policy
Ashley Gromis and Ka-Yuet Liu
110(7), pp. 1084–1091

VACCINE EXEMPTIONS
The Emergence of Spatial Clustering in Medical Vaccine Exemptions Following California Senate Bill 277, 2015–2018
Immunization/Vaccines, Health Policy
Risk factors for disease progression in COVID-19 patients
Coronavirus disease (COVID-19) is rapidly spreading worldwide. Although 10–20% of patients with COVID-19 have severe symptoms, little is known about the risk factors related to the aggravation of COVID-19 symp...
Authors: Min Cheol Chang, Yu-Kyung Park, Bong-Ok Kim and Donghwi Park
Why the COVID-19 pandemic should be a call for action to advance equitable access to medicines

Authors: Jillian C. Kohler and Tim K. Mackey
Citation: BMC Medicine 2020 18:193
Content type: Commentary
Published on: 25 June 2020

Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review

Major infectious disease outbreaks are a constant threat to human health. Clinical research responses to outbreaks generate evidence to improve outcomes and outbreak control. Experiences from previous epidemics have identified multiple challenges to undertaking timely clinical research responses. This scoping review is a systematic appraisal of political, economic, administrative, regulatory, logistical, ethical and social (PEARLES) challenges to clinical research responses to emergency epidemics and solutions identified to address these.

Authors: Louise Sigfrid, Katherine Maskell, Peter G. Bannister, Sharif A. Ismail, Shelui Collinson, Sadie Regmi, Claire Blackmore, Eli Harriss, Kajsa-Stina Longuere, Nina Gobat, Peter Horby, Mike Clarke and Gail Carson
Citation: BMC Medicine 2020 18:190
Content type: Research article
Published on: 25 June 2020

Development of a TB vaccine trial site in Africa and lessons from the Ebola experience
There is a dire need for a more efficacious TB vaccine. To deploy such vaccines, trials are needed in sites that combine high disease incidence and research infrastructure. We describe our twelve-year experience building a TB vaccine trial site in contrast to the process in the recent Ebola outbreak. There are additional differences. Relative to the Ebola pipeline, TB vaccines have fewer trials and a paucity of government and industry led trials. While pathogens have varying levels of difficulty in the development of new vaccine candidates, there yet appears to be greater interest in funding and coordinating Ebola interventions. TB is a global threat that requires similar concerted effort for elimination.


Citation: BMC Public Health 2020 20:999
Content type: Research in practice
Published on: 26 June 2020

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 27 June 2020)
[No new digest content identified]

BMJ Open
May 2020 - Volume 10 - 5
https://bmjopen.bmj.com/content/10/6
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 98, Number 6, June 2020, 373-440
https://www.who.int/bulletin/volumes/98/6/en/
[Reviewed earlier]

Child Care, Health and Development
Volume 46, Issue 4 Pages: 397-536 July 2020
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 107, Issue 6 Pages: 1263-1457 June 2020
[Reviewed earlier]

Clinical Therapeutics
http://www.clinicaltherapeutics.com/current
[New issue; No digest content identified]

Clinical Trials
Volume 17 Issue 3, June 2020
https://journals.sagepub.com/toc/ctja/17/3
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 27 June 2020]
[No new digest content identified]

Contemporary Clinical Trials
Volume 94   July 2020
[New issue; No digest content identified]

The CRISPR Journal
Volume 3, Issue 3 / June 2020
https://www.liebertpub.com/toc/crispr/3/3
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 8, Issue 2, June 2020
https://link.springer.com/journal/40142/8/2
[Reviewed earlier]

Current Opinion in Infectious Diseases
June 2020 - Volume 33 - Issue 3
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Developing World Bioethics
Volume 20, Issue 2 Pages: 61-114 June 2020
https://onlinelibrary.wiley.com/toc/14718847/current
EDITORIAL
The ethical challenges of the SARS-CoV-2 pandemic in the global south and the global north – same and different
Udo Schuklenk
Pages: 62-64
Ethical principles for promoting health research data sharing with sub-Saharan Africa

Evelyn Anane-Sarpong, Tenzin Wangmo, Marcel Tanner
Pages: 86-95
First Published: 21 May 2019

Development in Practice
Volume 30, Issue 3, 2020
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 14 - Issue 2 - April 2020
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 44, Issue 3  Pages: 433-618  July 2020
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 21  Issue 6  4 June 2020
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 26, Number 6—June 2020
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 31  June 2020
https://www.sciencedirect.com/journal/epidemics/vol/31/suppl/C
[Reviewed earlier]

Epidemiology and Infection
Volume 148 - 2020
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 42, Issue 3  Pages: 1-44  May–June 2020
https://onlinelibrary.wiley.com/toc/25782363/current

Perspectives of minors and parents • Non-English speakers • Covid-19 and other infectious diseases
[Reviewed earlier]

The European Journal of Public Health
Volume 30, Issue 3, June 2020
[Reviewed earlier]

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 27 June 2020]

Data Note metrics  AWAITING PEER REVIEW

Younger ages at risk of Covid-19 mortality in communities of color
[version 1; peer review: awaiting peer review]
Keith P. Klugman, Solomon Zewdu, Barbara E. Mahon, Scott F. Dowell, Padmini Srikantiah, Kayla F. Laserson, Jordan W. Tappero, Anita K. Zaidi, Trevor Mundel
Peer Reviewers Invited
Funder: Bill and Melinda Gates Foundation
PUBLISHED 26 Jun 2020

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 27 June 2020]
[No new digest content identified]

Global Health Action
Volume 12, 2019  Issue 1
https://www.tandfonline.com/toc/zgha20/12/sup1?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
2020 | Volume 8 | Number 2
http://www.ghspjournal.org/content/current
[Reviewed earlier]
**Global Public Health**
Volume 15, 2020  Issue 7
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

**Globalization and Health**
http://www.globalizationandhealth.com/
[Accessed 27 June 2020]

*Artificial intelligence in health care: laying the Foundation for Responsible, sustainable, and inclusive innovation in low- and middle-income countries*

The World Health Organization and other institutions are considering Artificial Intelligence (AI) as a technology that can potentially address some health system gaps, especially the reduction of global health...

Authors: Hassane Alami, Lysanne Rivard, Pascale Lehoux, Steven J. Hoffman, Stéphanie Bernadette Mafalda Cadeddu, Mathilde Savoldelli, Mamane Abdoulaye Samri, Mohamed Ali Ag Ahmed, Richard Fleet and Jean-Paul Fortin

Citation: Globalization and Health 2020 16:52
Content type: Debate
Published on: 24 June 2020

*Globalisation in the time of COVID-19: repositioning Africa to meet the immediate and remote challenges*

The COVID-19 pandemic has ushered in a new climate of uncertainty which is fuelling protectionism and playing into nationalist narratives. Globalisation is under significant threat as governments scramble to r...

Authors: Sanni Yaya, Akaninyene Otu and Ronald Labonté

Citation: Globalization and Health 2020 16:51
Content type: Commentary
Published on: 24 June 2020

**Health Affairs**
Vol. 39, No. 6   June 2020
https://www.healthaffairs.org/htlaff/current

*Rural Health, Behavioral Health & More*
[Reviewed earlier]

**Health and Human Rights**
https://www.hhrjournal.org/
[Accessed 27 June 2020]

Recent Viewpoints

*Learning from the Past: COVID-19 and Affordable Health Treatment*
Diya Uberoi, 25 June 2020

**Health Economics, Policy and Law**
**Articles**

*Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study*
Elena Nicod, Laia Maynou, Erica Visintin, John Cairns
Published online by Cambridge University Press: 06 September 2019, pp. 386-402

**Health Policy and Planning**
Volume 35, Issue 6, July 2020
https://academic.oup.com/heapol/issue/35/5

*Health systems constraints and facilitators of human papillomavirus immunization programmes in sub-Saharan Africa: a systematic review*
Edina Amponsah-Dacosta, Benjamin M Kagina, Jill Olivier

**Health Research Policy and Systems**
http://www.health-policy-systems.com/content
[Accessed 27 June 2020]
[No new digest content identified]

**Human Gene Therapy**
Volume 31, Issue 11-12 / June 2020
https://www.liebertpub.com/toc/hum/31/11-12
[Reviewed earlier]

**Humanitarian Exchange Magazine**
Number 77, March 2020

*Responding to Ebola in the Democratic Republic of Congo*
by Humanitarian Practice Network

This edition of Humanitarian Exchange, co-edited with Anne Harmer, focuses on the response to the Ebola outbreak in the Democratic Republic of Congo (DRC). Although at the time of publication the outbreak appeared to have ended, over its course it claimed 2,200 lives, with more than 3,300 infected, making this the world’s second largest outbreak ever.

In the lead article, Natalie Roberts reflects on the extent to which humanitarian actors have applied learning from the outbreak in West Africa in 2014–2016. Richard Kojan and colleagues report on the NGO ALIMA’s flexible, patient-centred approach to reducing mortality, Marcela Ascuntar reflects on lessons learned from community feedback and Bernard Balibuno, Emanuel Mbuna Badjonga and Howard Mollett highlight the crucial role faith-based organisations have played in the response. In their article, Theresa Jones, Noé Kasali and Olivia Tulloch outline the
work of the Bethesda counselling centre in Beni, which provides support to grieving families. Reflecting on findings from a recent assessment by Translators without Borders, Ellie Kemp describes the challenges involved in providing clear and accessible information on Ebola and the response, and Sung Joon Park and colleagues explain how humane care and treatment can help increase trust and confidence in the response. Stephen Mugamba and his co-authors highlight the importance of community involvement in Ebola research, and Gillian McKay and her co-authors examine the impact of the Ebola outbreak and response on sexual and reproductive health services.

Stacey Mearns, Kiryn Lanning and Michelle Gayer present an Ebola Readiness Roadmap to support NGOs in preparing for an outbreak, while Edward Kumakech, Maurice Sadlier, Aidan Sinnott and Dan Irvine report on a Gap Analysis tool looking at the communication, community engagement and compliance tracking activities that need to be in place before an Ebola vaccine is deployed. Emanuele Bruni and colleagues describe the development of a new monitoring and evaluation framework for strategic response planning. The edition ends with an article by Adelicia Fairbanks, who argues for an acceptance strategy in the DRC to improve security and access for responding agencies.

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)
Volume 16, Issue 5, 2020
http://www.tandfonline.com/toc/khvi20/current
Special Issue: Vaccine Acceptance
[Reviewed earlier]

**Infectious Agents and Cancer**
http://www.infectagentscancer.com/content
[Accessed 27 June 2020]
[No new digest content identified]

**Infectious Diseases of Poverty**
http://www.idpjournal.com/content
[Accessed 27 June 2020]
[No new digest content identified]

**International Health**
Volume 12, Issue 3, May 2020,
https://academic.oup.com/inthealth/issue/12/3
[Reviewed earlier]

**International Journal of Community Medicine and Public Health**
Vol 7, No 7 (2020) July 2020
https://www.ijcmph.com/index.php/ijcmph/issue/view/64
Original Research Articles
Vaccination coverage and factors associated with incomplete childhood vaccination among children aged 12-59 months in Miagao, Iloilo, Philippines
This study aimed to determine the vaccination coverage, timeliness, and maternal-related factors associated with incomplete vaccination of children in Miagao, Iloilo, Philippines. Serafin O. Malecosio, M. Jascha Lane D. Celis, Anarey M. Deopido, Katie B. Delicana, Keanah Marie F. Kang Bacale, Van Karlo L. Labasan, Riza Mae C. Ladiao, Kriza Marie D. Militante, Jaypee M. Paguntalan, Von Erjun P. Sabusap
DOI: 10.18203/2394-6040.ijcph20202971

Childhood immunisation knowledge and timeliness among caregivers of children 0-5 years, attending immunisation clinic of a medical college in West Bengal
Suman Das, Tapas K. Sarkar, Nirmal K. Mandal
DOI: 10.18203/2394-6040.ijcph20203012

International Journal of Epidemiology
Volume 49, Issue Supplement_1, April 2020
https://academic.oup.com/ije/issue/49/Supplement_1

Big Data, Small Area
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 13 Issue 3 2020
https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/2
Table of Contents
[Reviewed earlier]

International Journal of Infectious Diseases
June 2020 Volume 95, p1-480
[Reviewed earlier]

JAMA Network
COVID-19 Update
These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA
June 23/30, 2020, Vol 323, No. 24, Pages 2445-2536
https://jamanetwork.com/journals/jama/currentissue

Viewpoint
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)An Unprecedented Partnership for Unprecedented Times
Francis S. Collins, MD, PhD; Paul Stoffels, MD
free access has active quiz has multimedia has audio
This Viewpoint describes how the National Institutes of Health is partnering with more than a dozen biopharmaceutical companies and multiple other agencies to develop an international strategy for a coordinated research response to the COVID-19 pandemic, including prioritizing vaccine and drug candidates.

**Audio Interview:** The NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Initiative

**COVID-19: Beyond Tomorrow**

**Planning for a COVID-19 Vaccination Program**
Sarah Schaffer DeRoo, MD, MA; Natalie J. Pudalov, BA; Linda Y. Fu, MD, MS
free access has active quiz

This Viewpoint describes the categories of concerns underlying vaccine hesitancy (necessity, safety, and freedom of choice), and proposes ways to educate the public now about the public health and individual benefits of a COVID-19 vaccine to enhance its rapid, widespread uptake when it becomes available.

**COVID-19: Beyond Tomorrow**

**Adverse Consequences of Rushing a SARS-CoV-2 Vaccine—Implications for Public Trust**
Brit Trogen, MD, MS; David Oshinsky, PhD; Arthur Caplan, PhD
free access has active quiz has multimedia has audio

This Viewpoint discusses the importance of carefully evaluating SARS-CoV-2 vaccine candidates for safety and efficacy in the context of political pressure to accelerate the process, widespread vaccine hesitancy and refusal, and distrust of science.

**Audio Interview:** Coronavirus Vaccine Development

**COVID-19: Beyond Tomorrow**

**The Equitable Distribution of COVID-19 Therapeutics and Vaccines**
Thomas J. Bollyky, JD; Lawrence O. Gostin, JD; Margaret A. Hamburg, MD
free access has active quiz

This Viewpoint proposes a framework for international cooperation among governments and organizations to replace competition and hoarding with equitable global distribution of COVID-19 therapeutics and vaccines as they are developed.

**Editorial**

**COVID-19—Looking Beyond Tomorrow for Health Care and Society**
Phil B. Fontanarosa, MD, MBA; Howard Bauchner, MD

**Research Letter**

**Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States**
Muthiah Vaduganathan, MD, MPH; Jeroen van Meijgaard, PhD; Mandeep R. Mehra, MD, MSc; et al.
free access
This pharmacoepidemiology study uses US pharmacy data to compare prescriptions for hydroxychloroquine/chloroquine and azithromycin in February to April 2020 vs 2019, and vs the top 10 most commonly prescribed drugs in the same year, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 15 Issue 3, July 2020
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
June 2020 - Volume 74 - 6
https://jech.bmj.com/content/74/6
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 13, Issue 2  Pages: 89-177  May 2020
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 16, Issue 1, 2020
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 31, Number 2, May 2020
https://muse.jhu.edu/issue/42391
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 22, Issue 3, June 2020
https://link.springer.com/journal/10903/22/3
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 18, 2020, Issue 2
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 221, Issue 11, 1 June 2020
Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines, reducing the global burden of coronavirus-related mortality and morbidity. Volunteers’ net risk in such studies could be acceptable under specific conditions.
Generation coronavirus?

The Lancet

Articles

Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial
Jessica E Manning, et al

Background
In animal models, immunity to mosquito salivary proteins protects animals against mosquito-borne disease. These findings provide a rationale to vaccinate against mosquito saliva instead of the pathogen itself. To our knowledge, no vector salivary protein-based vaccine has been tested for safety and immunogenicity in humans. We aimed to assess the safety and immunogenicity of Anopheles gambiae saliva vaccine (AGS-v), a peptide-based vaccine derived from four A gambiae salivary proteins, in humans.

The Lancet Child & Adolescent Health

Jun 2020 Volume 4 Number 6 p407-478, e12-e16
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]
**Lancet Digital Health**  
Jun 2020  Volume 2  Number 6e268-e330  
[Reviewed earlier]

**Lancet Global Health**  
Jun 2020  Volume 8  Number 6  e737-e857  
[Reviewed earlier]

**Lancet Infectious Diseases**  
Jun 2020  Volume 20  Number 6  p629-754, e116-e147  
[Reviewed earlier]

**Lancet Public Health**  
Jun 2020  Volume 5  Number 6  e297-e360  
[Reviewed earlier]

**Lancet Respiratory Medicine**  
Jun 2020  Volume 8  Number 6  p527-646, e43-e54  
[Reviewed earlier]

**Maternal and Child Health Journal**  
Volume 24, Issue 6, June 2020  
[Reviewed earlier]

**Medical Decision Making (MDM)**  
Volume 40 Issue 4, May 2020  
[New issue; No digest content identified]

**The Milbank Quarterly**  
A Multidisciplinary Journal of Population Health and Health Policy  
Volume 98, Issue 2  Pages: 223-617  June 2020  
[Reviewed earlier]
Nature
Volume 582 Issue 7813, 25 June 2020
http://www.nature.com/nature/current_issue.html

Editorial | 23 June 2020
Getting out of the World Health Organization might not be as easy as Trump thinks
There is no process for member countries to withdraw. The United States should stay and help to reform the agency from within.

Nature Biotechnology
Volume 38 Issue 6, June 2020
https://www.nature.com/nbt/volumes/38/issues/6

[Reviewed earlier]

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 27 June 2020)
[No new digest content identified]

Nature Genetics
Volume 52 Issue 6, June 2020
[Reviewed earlier]

Nature Medicine
Volume 26 Issue 6, June 2020
https://www.nature.com/nm/volumes/26/issues/6
[Reviewed earlier]

Nature Reviews Genetics
Volume 21 Issue 6, June 2020
https://www.nature.com/nrg/volumes/21/issues/6
[Reviewed earlier]

Nature Reviews Immunology
Volume 20 Issue 6, June 2020
[Reviewed earlier]

Nature Reviews Drug Discovery
Volume 19 Issue 6, June 2020
COVID-19 in jails and prisons: A neglected infection in a marginalized population
Carlos Franco-Paredes, Katherine Jankousky, Jonathan Schultz, Jessica Bernfeld, Kimberly Cullen, Nicolas G. Quan, Shelley Kon, Peter Hotez, Andrés F. Henao-Martínez, Martin Krsak
Viewpoints | published 22 Jun 2020 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0008409
Review
COVID-19 in Children: An Ample Review
Ciucu IM
Published Date: 25 June 2020

Science
26 June 2020 Vol 368, Issue 6498
http://www.sciencemag.org/current.dtl
Policy Forum
“Explaining” machine learning reveals policy challenges
By Diane Coyle, Adrian Weller
Science26 Jun 2020 : 1433-1434 Restricted Access
The need to make objectives explicit may expose policy trade-offs that had previously been implicit and obscured
Summary
There is a growing demand to be able to “explain” machine learning (ML) systems' decisions and actions to human users, particularly when used in contexts where decisions have substantial implications for those affected and where there is a requirement for political accountability or legal compliance (1). Explainability is often discussed as a technical challenge in designing ML systems and decision procedures, to improve understanding of what is typically a “black box” phenomenon. But some of the most difficult challenges are nontechnical and raise questions about the broader accountability of organizations using ML in their decision-making. One reason for this is that many decisions by ML systems may exhibit bias, as systemic biases in society lead to biases in data used by the systems (2). But there is another reason, less widely appreciated. Because the quantities that ML systems seek to optimize have to be specified by their users, explainable ML will force policy-makers to be more explicit about their objectives, and thus about their values and political choices, exposing policy trade-offs that may have previously only been implicit and obscured. As the use of ML in policy spreads, there may have to be public debate that makes explicit the value judgments or weights to be used. Merely technical approaches to “explaining” ML will often only be effective if the systems are deployed by trustworthy and accountable organizations.

Science Translational Medicine
24 June 2020 Vol 12, Issue 549
https://stm.sciencemag.org/
[New issue; No digest content identified]

Social Science & Medicine
Volume 253 May 2020
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 27 June 2020]
[No digest content identified]

**Travel Medicine and Infectious Diseases**
Volume 35  May–June 2020
[New issue; No digest content identified]

**Tropical Medicine & International Health**
Volume 25, Issue 6  Pages: i-iv, 645-750  June 2020
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

**Vaccine**
Volume 38, Issue 29  Pages 4507-4650 (15 June 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/29
*Short communication  Abstract only*

**Are vaccinated measles cases protected against severe disease?**
M. Bonneton, D. Antona, K. Danis, F. Aït-Belghiti, D. Levy-Bruhl
Pages 4516-4519

*Research article  Open access*

**High overall confidence in childhood vaccination in Norway, slightly lower among the unemployed and those with a lower level of education**
Anneke Steens, Pawel Stefanoff, Anita Daae, Didrik F Vestrheim, Marianne A Riise Bergsaker
Pages 4536-4541

*Research article  Abstract only*

**From bad to worse: The representation of the HPV vaccine Facebook**
Monique L.R. Luisi
Pages 4564-4573

*Research article  Abstract only*

**Increasing healthcare workers’ uptake of seasonal influenza vaccination in a tertiary-care pediatric hospital in Greece with a low-cost, tailor-made, multifaceted strategy**
Ioannis Kopsidas, Grammatiki-Christina Tsopela, Stefania Maroudi-Manta, Eleni Kourkouni, ...
Susan E. Coffin
Pages 4609-4615

*Research article  Abstract only*

**Measles vaccination of young infants in China: A cost-effectiveness analysis**
Cara Bess Janusz, Abram L. Wagner, Nina B. Masters, Yaxing Ding, ...
Matthew L. Boulton
Pages 4616-4624
**Strengthening the Evidence-Based Approach to Guiding Effective Influenza Vaccination Policies**

by Giovanna Elisa Calabrò, Maria Lucia Specchia, Sara Boccalini, Donatella Panatto, Caterina Rizzo, Stefano Merler, Anna Maria Ferriero, Maria Luisa Di Pietro, Paolo Bonanni and Chiara de Waure

Vaccines 2020, 8(3), 342; https://doi.org/10.3390/vaccines8030342 (registering DOI) - 27 Jun 2020

**Abstract**

The availability of several effective and safe vaccines enables health systems to counteract annual influenza epidemics. However, the criteria of appropriateness and sustainability require that each citizen should receive the right vaccine. The value of each vaccine can be assessed within well-known frameworks.

**Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines**

by Olufemi Samuel Folorunso and Olihile M. Sebolai

Vaccines 2020, 8(3), 341; https://doi.org/10.3390/vaccines8030341 (registering DOI) - 27 Jun 2020

**Abstract**

Safety, efficacy, and cost-effectiveness are paramount to vaccine development. Following the isolation of rotavirus particles in 1969 and its evidence as an aetiology of severe dehydrating diarrhoea in infants and young children worldwide, the quest to find not only an acceptable and reliable

**Value in Health**

June 2020 Volume 23, Issue 6, p677-826
https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0008-8
[Reviewed earlier]

---

* From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

No new digest content identified.
**Media/Policy Watch**

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

**The Atlantic**
http://www.theatlantic.com/magazine/
*Accessed 27 June 2020*
[No new, unique, relevant content]

**BBC**
http://www.bbc.co.uk/
*Accessed 27 June 2020*
Health
**Coronavirus: Human trial of new vaccine begins in UK**
24 June 2020

**The Economist**
http://www.economist.com/
*Accessed 27 June 2020*
[No new, unique, relevant content]

**Financial Times**
http://www.ft.com/home/uk
*Accessed 27 June 2020*
Analysis  UK politics & policy
**Coronavirus: the global race for a vaccine | FT Interview**
June 25, 2020

**Forbes**
http://www.forbes.com/
*Accessed 27 June 2020*
Jun 26, 2020
**Frustrated Fauci? How America Lost The First Wave Of The Pandemic**
On Friday afternoon, amidst a soaring number of Covid-19 cases across the country, Dr. Fauci seemed frustrated. Which begs the question: is America is losing ground in the fight against the pandemic?
By Seth Cohen  Contributor

Jun 26, 2020
How Does Moderna’s Covid Vaccine Timing Compare With JNJ And Pfizer?
Modernina is seen as the front-runner in the race to develop a Covid-19 vaccine. The clinical-stage biotech company has phase 2 trials underway for its vaccine candidate mRNA-1273 and is expected to commence phase 3 trials in July, in collaboration with the U.S. National Institutes of Health...
By Trefis Team  Contributor

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 27 June 2020
[No new, unique, relevant content]

Foreign Policy
http://foreignpolicy.com/
Accessed 27 June 2020  [No new, unique, relevant content]
[No new, unique, relevant content]

The Guardian
http://www.guardiannews.com/
[No new, unique, relevant content]

New Yorker
http://www.newyorker.com/
Accessed 27 June 2020
Letter from the U.K.
The Lancet Editor’s Wild Ride Through the Coronavirus Pandemic
How Richard Horton balances science and politics.
By Sam Knight  27 June 2020

New York Times
http://www.nytimes.com/
Accessed 27 June 2020
U.S.
Global COVID-19 Fundraising Meeting Raises $6.9 Billion, Leaders Want Vaccine for All
A global fundraising meeting on Saturday raised 6.15 billion euros ($6.9 billion) from the United States, the European Commission and numerous countries to fight COVID-19, with many participants stressing that an eventual vaccine should be available to anyone who needs it.
By Reuters
By Reuters  27 June 2020

Americas
Brazil Signs Agreement to Produce AstraZeneca’s Experimental COVID-19 Vaccine
Brazil announced on Saturday that it had signed a $127 million agreement to start producing locally an experimental vaccine developed by AstraZeneca that has shown promise to fight the COVID-19 pandemic.
By Reuters

U.S.

**Vaxart Says Potential COVID-19 Vaccine Picked for 'Operation Warp Speed'**

Vaxart Inc said on Friday it would test its experimental oral COVID-19 vaccine on monkeys infected with the new coronavirus in a study funded by the Trump administration's vaccine-acceleration program called "Operation Warp Speed".
By Reuters  26 June 2020

Africa

**Africa Urges No 'Obstacles' to a COVID-19 Vaccine for All**

Governments around the world should “remove all obstacles” to swift and equitable distribution of any successful COVID-19 vaccine, including by making all intellectual property and technologies immediately available, African countries said Thursday.
By The Associated Press  25 June 2020

Asia Pacific

**Vaccine Against COVID-19 Not Certain, Maybe in a Year: WHO**

It is not certain that scientists will be able to create an effective vaccine against the coronavirus that has caused the COVID-19 pandemic, but it could take a year before one were to be invented, the head of the World Health Organisation said.
By Reuters  25 June 2020

Europe

**Germany Increases Donation to WHO but Demands Reforms**

Germany on Thursday announced that it is giving half a billion euros to support the World Health Organization amid the COVID-19 pandemic, but said reforms are necessary to make the agency more transparent and accountable.
By The Associated Press  25 June 2020

Washington Post

[https://www.washingtonpost.com/](https://www.washingtonpost.com/)
Accessed 27 June 2020

**Siddhartha Mukherjee says having a coronavirus vaccine by winter is an 'ambitious goal'**

Washington Post Live · Jun 24, 2020

*  *  *  *  *

**Think Tanks et al**

Brookings
[http://www.brookings.edu/](http://www.brookings.edu/)
Accessed 27 June 2020
Coronavirus (COVID-19) Economics
Global macroeconomic scenarios of the COVID-19 pandemic
Warwick J. McKibbin and Roshen Fernando
Thursday, June 25, 2020

Coronavirus (COVID-19) Economics
The effects of the coronavirus pandemic in emerging market and develop
Pinelopi K. Goldberg and Tristan Reed
Thursday, June 25, 2020

Center for Global Development [to 27 June 2020]
http://www.cgdev.org/page/press-center
Accessed 27 June 2020
[No new relevant content]

Chatham House [to 27 June 2020]
https://www.chathamhouse.org/
[No new relevant content]

CSIS
https://www.csis.org/
Accessed 27 June 2020
[No new relevant content]

Council on Foreign Relations
http://www.cfr.org/
Accessed 27 June 2020
June 25, 2020
South Africa
Trials for COVID-19 Vaccine Candidate Begin in South Africa
Trials of the Jenner Institute’s vaccine are taking place in Brazil, the United Kingdom Brazil, and South Africa, and the other trials also appear to have begun on June 24. According to the WHO, there are 220 vaccine candidates are in development.
Blog Post by John Campbell Africa in Transition

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 27 June 2020
[No new relevant content]

* * * * * * *
Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children’s Hospital of Philadelphia [CHOP].

Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Moderna Therapeutics (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.